Short- and long-term hemodynamic response to octreotide in portal hypertensive patients: A double-blind, controlled study

Liver

Volumn 16, Issue 4, 1996, Pages 225-234

  Zironi, G ^a   Rossi, C ^b   Siringo, S ^a   Galaverni, C ^b   Gaiani, S ^a   Piscaglia, F ^a   Bolondi, L ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Doppler flowmetry; Hepatic hemodynamics; Octreotide; Portal hypertension

Indexed keywords

HYPOTHALAMUS RELEASE INHIBITING FACTOR; OCTREOTIDE;

ADULT; AGED; ARTERY RESISTANCE; ARTICLE; BLOOD FLOW VELOCITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPPLER FLOWMETRY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; HEART RATE; HEMODYNAMICS; HEPATIC VEIN; HUMAN; LIVER VEIN; MALE; MEAN ARTERIAL PRESSURE; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; SUPERIOR MESENTERIC ARTERY; VEIN CATHETERIZATION; VENOUS PRESSURE;

EID: 0029740238     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0676.1996.tb00733.x     Document Type: Article

References (39)

1. GUILLEMIN R. Hypothalamic peptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973: 179: 77-79.
2. MORTIMER C H, CARR D, LIND T, et al. Growth hormone release-inhibiting hormone: effects on circulating glucagon, insulin and growth hormone in normal, diabetic, acromegalic and hypopituitary patients. Lancet 1974: i: 697-701.
3. BLOOM S R, MORTIMER C H, THORNER M O, et al. Inhibition of gastrin and gastric-acid secretion by growth hormone release-inhibiting hormones. Lancet 1974: ii: 1106-1109.
4. RAPTIS S, SCHLEGEL W, LEHMANNE, et al. Effects of somatostatin on the exocrine pancreas and the release of duodenal hormones. Metabolism 1978: 27 (suppl.): 1321-1328.
5. SAMNEGARD H, THULIN L, ANDREEN TYDEN G, HALLBERG D, EFENDIC S. Circulatory effects of somatostatin in anaesthetised dogs. Acta Chir Scand 1979: 145: 209-212.
6. TYDEN S, SAMNEGARD H, THULIN L, MUHRBECK O, EFENDIC S. Circulatory effects of somatostatin in anaesthetised man. Acta Chir Scand 1979: 145: 443-446.
7. BOSCH J, KRAVETZ D, RODÉS J. Effect of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. Gastroenterology 1981: 80: 518-525.
8. TYDEN G, SAMNEGARD H, THULIN L, et al. Treatment of bleeding oesophageal varices with somatostatin (letter). N Engl J Med 1978: 299: 1466.
9. THULIN H, TYDEN G, SAMNEGARD H, et al. Treatment of bleeding oesophageal varices with somatostatin. Acta Chir Scand 1979: 145: 395-399.
10. KRAVETZ D, BOSCH J, TERES J, BOUIX J, RIMOLA A, RODES J. Comparison of intravenous somatostatin and vasopressin infusion in treatment of acute variceal hemorrhage. Hepatology 1984: 4: 442-446.
11. JENKINS S A, BAXTER J N, CORBETT W, DEVITT P, WARE J, SHIELDS R. A prospective randomized controlled trial comparing somatostatin and vasopressin in controlling acute variceal hemorrhage. Br Med J 1985: 290: 275-278.
12. BURROUGHS A K, MCCORMICK P A, HUGHES M D, SPRENGERS D, D'HEYGERE F, MCINTYRE N. Randomized, double-blind, placebo-controlled trial of somatostatin for variceal bleeding. Gastroenterology 1990: 99: 1388-1395.
13. VALENZUELA J E, SCHUBERT T, FOGEL M R, et al. A multicenter, randomized, double-blind trial of somatostatin in the management of acute hemorrhage from esophageal varices. Hepatology 1989: 10: 958-961.
14. BAUER W, BRINER U, DOEPFNER W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982: 31: 1133-1140.
15. DEL POZO E, NEUFELD M, SCHLUTER K, et al. Endocrine profile of a long-acting somatostatin derivative SMA 201-995: study in normal volunteers following subcutaneous administration. Acta Endocrinol 1986: 111: 433-439.
16. KUTZ K, NUESCH E, ROSENTHALER J. Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroent 1986: 21 (suppl. 119): 65-72.
17. JENKINS S A, BAXTER J N, CORBETT W A, SHIELDS R. Effects of a somatostatin analogue SMS 201-995 on hepatic hemodynamics in the pig and on intravariceal pressure in man. Br J Surg 1985: 72: 1009-1012.
18. CERINI R, LEE S S, HADENGUE A, KOSHY A, GIROD C, LEBREC D. Circulatory effects of somatostatin analogue in two conscious rat models of portal hypertension. Gastroenterology 1988: 94: 703-708.
19. WAHREN J, ERIKSSON L S. The influence of a long-acting somatostatin analogue on splanchnic hemodynamics and metabolism in healthy subjects and patients with liver cirrhosis. Scand J Gastroenterol 1986: 21: 103-108.
20. BURROUGHS A K, SANTANA I A, DUX T, et al. Effect of a long-acting analogue of somatostatin (SMS 201-995) on hepatic venous pressures and azygous blood flow in cirrhotics. Gut 1985: 26: A562.
21. ERIKSSON L S, BRUNDIN T, SODERLUND C, WAHREN J. Haemodynamic effects of a long-acting somatostatin analogue in patients with liver cirrhosis. Scand J Gastroenterol 1987: 22: 919-925.
22. LIN H C, TSAI Y T, LEE F Y, et al. Hemodynamic evaluation of octreotide in patients with hepatitis B-related cirrhosis. Gastroenterology 1992: 103: 229-234.
23. SUBRAMANYAM B R, BALTHAZAR E J, MADAMBA M R, et al. Sonography of porto-systemic venous collaterals in portal hypertension. Radiology 1983: 146: 161-166.
24. BOLONDI L, GANDOLFI L, ARIENTI V, et al. Ultrasonography in the diagnosis of portal hypertension: diminished response of portal vessels to respiration. Radiology 1982: 142: 167-172.
25. PUGH R W H, MURRAY-LYON I M, DAWSON J L, PANTRONI M C, WILLIAMS R. Transaction of the esophagus for bleeding oesophageal varices. Br J Surg 1973: 60: 646-649.
26. GILL R W. Measurement of blood flow by ultrasound: accuracy and sources of error. Ultrasound Med Biol 1985: 4: 625-641.
27. GILL R W. Pulsed Doppler with B-mode imaging for quantitative blood flow measurement. Ultrasound Med Biol 1979: 5: 223-235.
28. ZIRONI G, GAIANI S, FENYVES D, RIGAMONTI A, BOLONDI L, BARBARA L. Value of measurement of mean portal flow velocity by Doppler flowmetry in the diagnosis of portal hypertension. J Hepatol 1992: 16: 298-303.
29. DAY S J, GRAHAM D F. Sample size and power for comparing two or more treatment groups in clinical trials. Br Med J 1989: 299: 663-665.
30. WEBB S C, KRIKLER D M, HENDY W G, ADRIAN T E, BLOOM S R. Electrophysiological actions of somatostatin on the atrioventricular junction in sinus rhythm and reentry tachycardia. Br Heart J 1986: 56: 236-241.
31. DE LA VILLA F M, SOLANO LOPEZ D, BOVEDA J, et al. Somatostatin and ventricular function in liver cirrhosis. Rev Clin Exp 1990: 186: 58-62.
32. MCCORMICK P A, SEIPALIAN A M, STANSBY G, et al. Superior mesenteric artery blood flow in man measured with intra-arterial Doppler catheters: effect of octreotide. J Hepatol 1993: 17: 20-27.
33. NAVASA M, BOSCH J, CHESTA, et al. Haemodynamic effects of subcutaneous administration of SMS 201-995 a long acting somatostatin analog in patients with cirrhosis and portal hypertension. J Hepatol 1988: 7 (suppl. 1): S64.
34. SIEBER C, GNADINGER M, DEL POZO E, SHAW S, WEIDMANN P. Effect of a new somatostatin analogue SMS 201-995 (sandostatin) on the renin-aldosterone axis. Clin Endocrin 1988: 28: 25-32.
35. COOPER A M, BRAATVEDT G D, QAMAR M I, et al. Fasting and postprandial splanchnic blood flow is reduced by a somatostatin analogue (octreotide) in man. Clin Sci 1991: 81: 169-175.
36. KRAVETZ D, BOSCH J, ARDERIU M T, et al. Effect of somatostatin on splanchnic hemodynamics and plasma glucagon in portal hypertensive rats. Am J Physiol 1988: 254: G322-G328.
37. TORNEBRANDT K, NOBIN A, OWMAN C H. Contractile and dilatory action of neuropeptides on isolated human mesenteric blood vessels. Peptides 1987: 8: 251-256.
38. ADRIAN T E, BARNES A J, LONG R G, et al. The effect of somatostatin analogs on secretion of growth, pancreatic, and gastrointestinal hormones in man. J Clin Endocrinol Metabol 1981: 53: 675-681.
39. MESCH C L, JOH T, KORTHUIS R J, GRANGER D N, BENOIT J N. Intestinal vascular sensitivity to vasopressin in portal hypertensive rats. Gastroenterology 1991: 100: 916-921.